Log in
Enquire now
‌

US Patent 11407789 Cell-penetrating compstatin analogs and uses thereof

Patent 11407789 was granted and assigned to Apellis Pharmaceuticals on August, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
Apellis Pharmaceuticals
Apellis Pharmaceuticals
0
Date Filed
December 18, 2020
0
Date of Patent
August 9, 2022
0
Patent Applicant
Apellis Pharmaceuticals
Apellis Pharmaceuticals
0
Patent Application Number
17126367
0
Patent Citations
‌
US Patent 10125171 Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
‌
US Patent 10407466 Methods of selecting compstatin mimetics
‌
US Patent 10308687 Cell-penetrating compstatin analogs and uses thereof
‌
US Patent 11040107 Dosing regimens and related compositions and methods
‌
US Patent 11001610 Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
‌
US Patent 10941184 Cell-penetrating compstatin analogs and uses thereof
‌
US Patent 10875893 Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
‌
US Patent 10035822 Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Patent Citations Received
‌
US Patent 12059413 Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction
0
‌
US Patent 11661441 Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
0
Patent Inventor Names
Pascal Deschatelets
0
Monica Gerber
0
Cedric Francois
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11407789
0
Patent Primary Examiner
‌
Julie Ha
0

Find more entities like US Patent 11407789 Cell-penetrating compstatin analogs and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.